<p><em>SNHG16</em>: A Novel Long-Non Coding RNA in Human Cancers</p>

Abstract

Long noncoding RNAs (lncRNAs) have recently been considered as central regulators in diverse biological processes controlling tumorigenesis. Small nucleolar RNA host gene 16 (SNHG16) is an important tumor-associated lncRNA mainly involved in tumorigenesis and progression by competing with endogenous RNA (ceRNA) which sponges tumor-suppressive microRNA (miRNA), and by its recruitment mechanism. SNHG16 is overexpressed in tumor tissues and cell lines of different kinds of cancers, and its presence is associated with a poor clinical prognosis. Reviewing all publications about SNHG16 revealed that it plays a key role in the different hallmarks that define human cancer, including promoting proliferation, activating migration and invasion, inhibiting apoptosis, affecting lipid metabolism and chemoresistance. This review highlights the role that the aberrant expression of SNHG16 plays in the development and progression of cancer, and suggests that SNHG16 may function as a potential biomarker and therapeutic target for human cancers.

Circulating long noncoding RNAs as potential biomarkers for stomach cancer: A systematic review and meta-analysis

“…Third, lncRNAs have complex biological functions and are closely related to tumorigenesis and development. Therefore, lncRNAs may be promising biomarkers for the early detection and prognosis of various cancers [56] .…”

Clinicopathological significance and prognosis of long noncoding RNA SNHG16 expression in human cancers: a meta-analysis

“…LncRNAs are involved in various cellular events and act as guides, signals, decoys, and dynamic scaffolds by modulating cancer hallmarks, including DNA damage, metastasis, immune escape, cell stemness, drug resistance, metabolic reprogramming, and angiogenesis [33]. LncRNAs contribute to epigenetic changes where lncRNAs have the potential to act as oncogenes and/or tumor suppressors [29]. Thus lncRNAs take an important part in cancer development and growth.…”

“…In recent years, many studies have demonstrated that abnormal expression of SNHG16 does not only correspond to one tumor, but also can been detected different tumor tissues from various systems [ 39 – 41 ]. And the mechanisms of SNHG16 in different tumor types are unclear and controversial [ 29 ]. Results from this meta-analysis indicated that overexpression of the lncRNA SNHG16 might serve as a prognostic factor in patients with digestive system cancers, urinary system cancers, and other system cancers (including glioma and non-small cell lung cancer), which could provide a basis for medical workers to evaluate the prognosis of patients and to help the decision-making process.…”

“…Moreover, the expression level of SNHG16 is closely related to TNM stage, tumor size, histological grade, overall survival (OS), and other clinical attributes [ 17 ]. And SNHG16 participates in regulating the biological functions of tumor cells through complex regulatory mechanisms, such as cell proliferation, migration, invasion and apoptosis [ 29 ]. Therefore, we conducted a meta-analysis to investigate whether the lncRNA SNHG16 can be used as a prognostic biomarker for human cancers.…”

Circulating long non-coding RNAs as potential biomarkers for stomach cancer: A systematic review and meta-analysis

“…Third, lncRNA has complex biological functions and is closely related to tumorigenesis and development. Therefore, lncRNA may contribute as a promising biomarker for the early detection and prognosis of various cancers (54).…”